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ABSTRACT (250 words) 32 
Background. Vascular endothelial dysfunction with associated oedema and organ 33 
failure is one of the hallmarks of sepsis. While a large number of microorganisms 34 
can cause sepsis, Staphylococcus aureus is one of the primary etiological agents. 35 
Currently there are no approved specific treatments for sepsis and therefore the 36 
initial management bundle focuses on cardiorespiratory resuscitation and mitigation 37 
against the immediate threat of uncontrolled infection. The continuous emergence of 38 
antibiotic resistant strains of bacteria urges the development of new therapeutic 39 
approaches for this disease. Objective. The objective of this study was to identify the 40 
molecular mechanisms leading to endothelial dysfunction as a result of 41 
Staphylococcus aureus binding. Methods. Stahpylococcus aureus Newman and 42 
clumping factor A-deficient binding to endothelium were measured in vitro and in the 43 
mesenteric circulation of C57Bl/6 mice. The effect of the αVβ3 blocker, cilengitide, 44 
on bacterial binding, endothelial VE-cadherin expression, apoptosis, proliferation and 45 
permeability were assessed.  Results. Here we show that the major Staphylococcus 46 
aureus cell wall protein clumping factor A binds to endothelial cell integrin αVβ3 in 47 
the presence of fibrinogen. This interaction results in disturbances in barrier function 48 
mediated by VE-cadherin in endothelial cell monolayers and ultimately cell death by 49 
apoptosis. Using a low concentration of cilengitide, ClfA binding to αVβ3 was 50 
significantly inhibited both in vitro and in vivo. Moreover, preventing Staphylococcus 51 
aureus from attaching to αVβ3 resulted in a significant reduction in endothelial 52 
dysfunction following infection. Conclusion. Inhibition of Staphylococcus aureus 53 
ClfA binding to endothelial cell αVβ3 using cilengitide prevents endothelial 54 
dysfunction.  55 
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ESSENTIALS 56 
• Staphylococcus aureus (S. aureus) binds and impairs function of vascular 57 
endothelial cells (EC) 58 
• We investigated the molecular signals triggered by S. aureus adhesion to 59 
endothelial cells  60 
• Inhibition of the EC integrin αvβ3 reduces S. aureus binding and rescues EC 61 
function 62 
• αvβ3 blockade represents an attractive target to treat S. aureus bloodborne 63 
infections 64 
 65 
 66 
 67 
 68 
 69 
 70 
 71 
 72 
 73 
 74 
 75 
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INTRODUCTION 76 
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated 77 
host response to infection[1]. There is an estimated 20 million new cases of sepsis 78 
worldwide per year with a mortality rate of up to 50%[2]. The vascular endothelium is 79 
a significant target of sepsis-induced events and endothelial pertubation underlies 80 
systemic injury in sepsis[3]. For example, bacteria binding to endothelial cells results 81 
in activation and granule mobilization. This leads to von Willebrand factor deposition 82 
on the surface of the endothelial cells which contributes to rapid platelet translocation 83 
and thrombus formation[4]. A concomitant decrease of anticoagulation factors, with a 84 
reduction of thrombomodulin at the surface of the endothelial cell and a reduction of 85 
circulating levels of protein C leads to clot formation and triggers disseminated 86 
intravascular coagulation[5]. A breakdown of the endothelial barrier results in fluid 87 
leakage into the extravascular space leading to life threatening oedema in septic 88 
patients[6]. The inflammatory response also plays a key role in the sepsis phenotype 89 
and an excessive or sustained inflammatory response contributes to the tissue 90 
damage and death[7]. At present there is no effective specific anti-sepsis treatment. 91 
Besides the administration of intravenous fluids and vasopressors required to 92 
stabilize the patients, the infection is treated with aggressive intravenous 93 
combination antimicrobial therapy, frequently with meagre success[8],[9].  94 
 95 
Recent evidence involving 14,000 ICU patients in 75 countries suggest that 96 
Staphylococcus aureus is one of the most frequently occurring underlying causes of 97 
sepsis and causes perturbation when it binds to the endothelium[10]. The success of 98 
S. aureus as an opportunistic pathogen in the cardiovascular system is due in part to 99 
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its expression of a wide array of Microbial Surface Components Recognising 100 
Adhesive Matrix Molecules (MSCRAMM’s)[11]. Using these MSCRAMM’s, S. aureus 101 
can attach either directly or indirectly to host cells to initiate infection. S. aureus 102 
clumping factor A (ClfA) is a major MSCRAMM and has already been shown to play 103 
a key role in bloodstream infection by binding to αIIbβ3 on platelets and inducing 104 
rapid thrombus formation under physiological conditions in vitro. Inhibition of αIIbβ3 105 
or using a strain deficient in expression of ClfA, prevents thrombus formation[12]. 106 
The integrin αIIbβ3 is platelet specific and not expressed on endothelial cells 107 
however, another β3 integrin, αVβ3, is expressed on endothelial cells and 108 
interestingly has been shown to be upregulated in sepsis patients[13].  109 
 110 
Using an ex vivo dynamic model of human endothelial cells, we identified a critical 111 
interaction between S. aureus ClfA and αVβ3 that results in endothelial cell 112 
apoptosis and loss of barrier integrity (increased permeability). Furthermore, we 113 
identified a compound that inhibits S. aureus from binding to endothelial cells and in 114 
doing so prevents the signals that result in apoptosis and increased permeability. 115 
These results have important implications for the treatment and management of 116 
sepsis.  117 
 118 
Materials and Methods  119 
Materials 120 
All reagents used in this study were sourced from Sigma (Wexford, Ireland) unless 121 
otherwise stated. Bacteria were a kind gift from Professor Timothy Foster (Trinity 122 
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College Dublin). Cilengitide was a kind gift from Professor Horst Kessler (Technical 123 
University of Munchen, Germany).  124 
 125 
Blood collection and plasma preparation 126 
Whole blood was collected from healthy donors and anticoagulated with hirudin 127 
(300U/ml). Plasma was obtained as described previously[14]. Approval for the 128 
collection of whole blood was obtained from the Ethics Committee in RCSI (REC 129 
679b). Informed consent was provided in accordance with the Declaration of 130 
Helsinki.  131 
 132 
Bacteria growth conditions  133 
Bacteria strains used in this study were: Staphylococcus aureus Newman Wildtype 134 
NCTC 8178[15], Staphylococcus aureus ΔClfA DU5876 (clfA::ErmR defective in 135 
clumping factor A) [16], Staphylococcus aureus ΔSpA DU5971 (spa::KaR; defective 136 
in Protein A) [17], Lactococcus lactis mock transfected NZ9800 (pKS80 empty 137 
vector) [18], Lactococcus lactis +ClfA NZ9800 (pNZ8037 ClfA ErmR) [19], 138 
Lactococcus lactis +ClfA PY NZ9800 (pNZ8037 ::clfa PY CamR , expressing ClfA 139 
where P336 and Y338 are replaced with serine and alanine respectively) [20], 140 
Lactococcus lactis +SpA NZ9800 (pKS80 spa) [21]. All strains were cultured 141 
anaerobically at 37°C overnight and prepared as described previously[12]. 142 
 143 
Cell culture conditions   144 
In order to develop a dynamic ex vivo model that represents the physiological state 145 
of human blood vessels, primary derived Human Aortic Endothelial Cells were 146 
cultured and subjected to haemodynamic shear force in Endothelial Cell Growth 147 
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Media as previously described (Promocell, Germany)[22]. Unless otherwise stated, 148 
endothelial cell infection was preceded by incubation with 10ng/mL TNFα for 4hr at 149 
37°C and 5% CO2, followed by exposure to plasma, fibrinogen (4mg/ml) or IgG (1-150 
8mg/mL) for 1hr. In some experiments cells were preincubated with the αVβ3 151 
antagonist, cilengitide (0.05µM), for 1hr in between the TNFα exposure and the 152 
addition of plasma/fibrinogen. 153 
  154 
Binding assays  155 
Sheared endothelial cells in the presence of TNFα and plasma/fibrinogen or 156 
40µg/mL of purified recombinant αVβ3 (R&D systems, UK) were immobilized onto 157 
microtitre plates, blocked with 1% BSA for 2hrs at 37ºC and incubated with 1x107 158 
SYBR green II stained bacteria at a MOI of 400 for a further hour at 37°C. In some 159 
experiments cilengitide was preincubated with the cells or purified protein for 1h prior 160 
to addition of the bacteria. Wells were finally washed gently to remove non-adhered 161 
bacteria. Fluorescence was read at 485/535 nm in a plate reader (1420 Victor V3, 162 
Perkin Elmer, Ireland) before (Reading1) and after (Reading2) the final wash. 163 
Number of adhered bacteria per well was computed as (Reading2/Reading1) x 164 
1x107. 165 
 166 
αvβ3 analysis by flow cytometry 167 
αVβ3 expression pre and post- activation with TNFα (10ng/ml for 4hrs) was 168 
measured by flow cytometry. Endothelial cells were incubated with anti-αVβ3 169 
(LM609) or istoype control. Primary antibodies were incubated with the endothelial 170 
cells for 1hr at 37ºC followed by a FITC-labelled secondary antibody in the dark. 171 
After 20 min incubation the samples were analysed on a flow cytometer (Becton 172 
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Dickinson, Oxford, UK) on the Fl-1 channel. Data were analysed using CellQuest 173 
software (Becton Dickinson). 174 
 175 
Dot blots and western blots 176 
Whole cell dot blots were carried out as previously described [23]. Briefly, a 10µl spot 177 
of bacteria was placed on a nitrocellulose membrane, allowed to dry at room 178 
temperature, blocked with 5% dry skimmed milk and probed with anti-mouse ClfA 179 
(1:1000) or anti-mouse SpA (Sigma, Ireland, 1:1000) antibodies. For western blots 180 
endothelial cells were lysed in RIPA buffer and proteins separated on a 10% SDS-181 
PAGE. Separated proteins were transferred onto nitrocellulose membranes, blocked 182 
for 1h with 5% milk and probed with mouse VE-cadherin primary antibody (Santa 183 
Cruz, 1:1000). Anti-rabbit or anti-mouse IgG conjugated to horseradish peroxidase 184 
(Biolegend, 1:5000) were used as the secondary antibodies. Proteins were detected 185 
using ECL chemiluminescence (Millipore, UK).  186 
 187 
Ca2+ mobilization in endothelial cells following infection 188 
Sheared endothelial cells  were loaded with the Ca2+ sensitive dye Fluo-4 AM (5µM, 189 
Molecular Probes) for 20 minutes. Endothelial cells were then perfused with HEPES 190 
buffer containing 10ng/mL TNFα and 0.4mg/mL fibrinogen, and switched to the 191 
same buffer containing bacteria after 2 minutes. Samples were excited at 488nm and 192 
>500nm emission was measured at 2 minute intervals. Live images were acquired 193 
using an epifluorescence microscope (Zeiss AxioObserverZ1). Timecourse of 194 
endothelial cell intracellular Ca2+ levels were expressed as Fluo-4 fluorescence F/F0 195 
(F0=initial fluorescence).  196 
 197 
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Immunofluorescence 198 
Endothelial cells were stained with either VE-cadherin mouse monoclonal (1:50, 199 
InVitrogen), vWf rabbit polyclonal (1:50, BD Biosciences), and fluoresced using a 200 
secondary Alexa-fluor® 488 donkey-anti rabbit or donkey-anti mouse (1:200, 201 
Invitrogen). Coverslips were mounted on slides with fluorescent mounting medium 202 
containing DAPI for nuclei staining (ProLong, Invitrogen). Control experiments were 203 
performed incubating samples with primary or secondary antibody alone. Images 204 
were acquired using an inverted epifluorescence microscope. For extracellular vWF 205 
quantification, 10 images were captured per field (Metamorph), background was 206 
subtracted, nuclei counted and vWf attributable fluorescence measured (ImageJ). 207 
Extracellular vWf was computed as fluorescence intensity per cell, dividing vWf 208 
fluorescence by the number of nuclei present in each image. 209 
 210 
Quantification of endothelial cell proliferation and apoptosis 211 
Endothelial cell proliferation was determined by counting cells on a haemocytometer 212 
in a 1:1 dilution with Trypan Blue after a 24h period and comparing it to the seeding 213 
density. Apoptosis was determined by flow cytometry. Following the 24h infection, 214 
endothelial cells were trypsinized, washed and resuspended in ice cold PBS. The 215 
endothelial cells were pelleted in FACS tubes and re-suspended in the reagent mix 216 
of TACS™ Annexin V Kits (AMS Biotechnology, Oxford) according to the 217 
manufacturer instructions. Endothelial cells were incubated in the dark at room 218 
temperature for 15mins and analyzed on a flow cytometer (BD FACSCanto™ II Flow 219 
Cytometer).  220 
 221 
Permeability assay 222 
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Endothelial barrier permeability was assessed as previously described[24]. Briefly, 223 
sheared endothelial cells were plated at a density 2x105 cells/mL on the upper 224 
chamber of hanging inserts, (Millicel, Millipore, pore size 0.4μM) and endothelial cell 225 
media was added to the lower chamber. Following infection, FITC dextran 226 
(250μg/mL; 40kDa) was added to the endothelial cells in the upper chamber. 227 
Permeability was determined after 24hrs by measuring the amount of FITC dextran 228 
that permeated through the endothelial cells into the lower chamber using a 229 
fluorescent plate reader (1420 Victor V3, Perkin Elmer). Data is expressed as a 230 
percentage of 100% permeability.  231 
 232 
Mesenteric Perfusion Model 233 
S. aureus binding to mice mesenteric endothelium was measuring as previously 234 
described[4]. Briefly, six to eight week old C57Bl/6 mice were fasted and 235 
anaesthetized with ketamine/xylazine (125/12.5 mg/kg, intraperitoneal).  The 236 
endothelium on the mesenteric circulation was exposed and activated with A23187 237 
(10mM). Bacteria were labelled with 5(6)-carboxy-fluorescein N-hydroxysuccinimidyl 238 
ester and injected through the jugular catheter. Time-lapse images were acquired 239 
using an inverted fluorescence microscope. Fluorescent signal in the blood vessel 240 
corresponding to bound bacteria was quantified manually for each frame and the 241 
average computed as arbitrary fluorescence units. In some experiments 23.5ng/kg 242 
cilengitide was added to the animals for 5mins before addition of bacteria. Animal 243 
experiments were approved by the Ethical Committee of the University of Leuven. 244 
 245 
Statistics 246 
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Data are presented as mean ± SEM. Experiments were carried out in triplicate with a 247 
minimum of three independent experiments. Statistical difference between groups 248 
was assessed by ANOVA with Tukey post-hoc test or t-test, as indicated. P<0.05 249 
was considered significant. 250 
 251 
RESULTS 252 
Staphylococcus aureus binds to endothelial cells grown under haemodynamic 253 
shear force.  254 
To examine the effect of shear stress on endothelial cell structure and S. aureus 255 
binding, monolayers of endothelial cells were grown under static conditions or 256 
exposed to fluid shear stress at 10dynes/cm2 for 24hrs to mimic the conditions 257 
arterial cells experience in vivo. Images show that endothelial cells grown under 258 
static conditions exhibit a random “cobble stone” morphology and exhibit a distinct 259 
lack of immunostaining for adherens junction protein Vascular Endothelium (VE)-260 
cadherin staining at the endothelial cell-cell border (Supplementary figure 1A). In 261 
contrast, endothelial cells sheared at 10dynes/cm2 aligned in the direction of flow 262 
and there was clear staining of VE-cadherin at the plasma membrane of the 263 
endothelial cells at sites of cell-cell contact (Supplementary figure 1B). Consistent 264 
with this, statically grown endothelial cells expressed less VE-cadherin protein than 265 
sheared endothelial cells (Supplementary figure 1C). Formation of adherens 266 
junctions by VE-cadherin contributes to the functional barrier role of the endothelium 267 
[25], and as such sheared endothelial cells  better represent the cellular morphology 268 
observed in the vasculature and constitute a more physiologically relevant model to 269 
study endothelial cell-bacteria interactions.   270 
 271 
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We observed no significant effect on S. aureus binding to sheared endothelial cells 272 
when either plasma proteins or TNFα were added separately. However, addition of 273 
human plasma and TNFα combined resulted in a significant increase in S. aureus 274 
binding to sheared endothelial cells (Figure 1). Interestingly, we also observed that 275 
S. aureus binding in the presence of plasma and TNFα is significantly higher for 276 
sheared endothelial cells than statically grown (Supplementary Figure 1D). Based on 277 
these observations, unless otherwise stated, all further experiments were performed 278 
on sheared endothelial cells in the presence of human plasma/fibrinogen and TNFα. 279 
 280 
Staphylococcus aureus ClfA mediates binding to sheared endothelial cells 281 
Major S. aureus cell wall proteins, Protein A (SpA) and ClfA have been previously 282 
identified as key players in the recognition of various host cells [12, 26]. Using 283 
isogenic mutants of these proteins we investigated their role binding to endothelial 284 
cells. A S. aureus mutant defective in expression of SpA (ΔSpA), failed to affect 285 
binding to sheared endothelial cells. In contrast, a S. aureus strain defective in 286 
expression of ClfA (ΔClfA) bound to a significantly lesser extent to endothelial cells 287 
(Figure 2A). Lack of expression of either SpA or ClfA on S. aureus was confirmed by 288 
dot blot (Figure 2C).  289 
 290 
To confirm our finding, ClfA was expressed in the surrogate host Lactococcus lactis. 291 
We chose L. lactis as it naturally lacks the virulence factors present in S. aureus, in 292 
particular ClfA and SpA. Consistent with our previous findings, expression of SpA in 293 
L. lactis failed to increase binding to the endothelial cells above the mock transfected 294 
control, whereas expression of ClfA resulted in significant binding to endothelial cells 295 
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(Figure 2B). Over expression of SpA and ClfA in the surrogate host L. lactis was 296 
confirmed by dot blot (Figure 2D).  297 
 298 
Fibrinogen acts as a bridge between ClfA and endothelial cells 299 
S. aureus often binds a plasma protein to ‘bridge’ the bacteria host cells[27]. 300 
Previously we and others demonstrated that ClfA is capable of binding the plasma 301 
proteins IgG and fibrinogen both individually and simultaneously [12, 20]. To 302 
determine if L. lactis ClfA is binding these plasma proteins we added purified IgG or 303 
fibrinogen to endothelial cells, followed by incubation with L. lactis ClfA. Our results 304 
showed that IgG (up to 8mg/mL) failed to achieve significant levels of L. lactis ClfA 305 
attachment to endothelial cells. In contrast, purified fibrinogen (4mg/ml) restored the 306 
ability of L. lactis ClfA to bind to endothelial cells at levels similar to those observed 307 
in the presence of plasma (Figure 2E). These results are consistent with our 308 
observations with S. aureus where there is a significant reduction in binding to 309 
endothelial cells in the absence of fibrinogen (Supplementary figure 2). Deletion of 310 
the amino acids in ClfA (ClfA-PY) critical for binding fibrinogen [20], significantly 311 
reduced in its ability to bind to endothelial cells compared to L. lactis ClfA (Figure 312 
2F).  313 
 314 
Staphylococcus aureus ClfA mobilizes calcium and elicits deposit of von 315 
Willebrand factor onto the surface of endothelial cells. 316 
Calcium is an important second messenger and mobilization in endothelial cells 317 
results in Weibel-Palade body secretion[28]. Von Willebrand factor (vWf) is the 318 
primary constituent of Weibel-Palade bodies and once secreted attaches to the 319 
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surface of endothelial cells creating a binding site for S. aureus proteins SpA[29] and 320 
von Willebrand factor binding protein (vwbp) [4]. The nature of the signal that results 321 
in vWf secretion following S. aureus binding is currently unknown. We therefore 322 
measured endothelial cell intracellular Ca2+ following L. lactis ClfA infection by 323 
loading cells with Fluo-4-AM and surface vWf levels by immunofluorescence. 324 
Uninfected endothelial cells exhibited background levels of Fluo-4 fluorescence over 325 
a 12min period (Figure 3A&D). Addition of mock L. lactis exerted no significant effect 326 
on baseline Fluo-4 fluorescence (Figure 3B&D). Addition of L. lactis ClfA resulted in 327 
a significant transient increase in Fluo-4 fluorescence in endothelial cells (Figure 328 
3C&D).  329 
Neither the uninfected nor mock transfected L. lactis resulted in secretion of vWf 330 
onto the surface of the endothelial cells (Figure 3E&F). Addition of L. lactis ClfA to 331 
the endothelial cells elicited a significant increase in vWf on the surface of the cells 332 
(Figure 3G&H). 333 
 334 
Staphylococcus aureus ClfA binds αVβ3 integrin on endothelial cells both in 335 
vitro and in vivo. 336 
A number of fibrinogen binding receptors have been previously described on 337 
endothelial cells including ICAM-1, α5β1 and αVβ3[30]. Preincubation of endothelial 338 
cells with monoclonal antibodies against ICAM-1 or α5β1 failed to have any effect on 339 
L. lactis  ClfA binding to endothelial cells (Figure 4A). Preincubation of endothelial 340 
cells with αVβ3 antagonist, cilengitide (0.05µM) significantly reduced L. lactis ClfA 341 
from binding to endothelial cells compared to the vehicle control (Figure 4A). To 342 
exclude the possibility that cytotoxic effects of cilengitide were the underlying cause 343 
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of reduction in L. lactis binding to endothelial cells, we examined the effects of 344 
cilengitide on endothelial cells alone. No adverse effects on growth, cytotoxicity, 345 
apoptosis or VE-cadherin expression was detected on endothelial cells preincubated 346 
with cilengitide for 24hrs (Supplementary figure 3A-F). Consistent with these 347 
findings, cilengitide also significantly inhibits S. aureus from binding to endothelial 348 
cells (Figure 4B). Preincubation of cilengitide with purified αVβ3 in the presence of 349 
fibrinogen significantly inhibited L. lactis ClfA from binding (Figure 4C). Consistent 350 
with the finding that αVβ3 is up regulated in sepsis patients [13] we also found that 351 
αVβ3 expression is increased by 51% on our sheared endothelial cells following 352 
TNFα treatment (Table 1).  353 
 354 
To validate our findings that ClfA binds to αVβ3 in vivo we used real-time 355 
videomicroscopy of the murine splanchnic veins and demonstrated rapid local 356 
accumulation of S. aureus on the vessel wall (Figure 5A&D). Innoculation of S. 357 
aureus ΔClfA resulted in a significant reduction in bacteria adhering to the vessel 358 
wall (Figure 5B&D). Furthermore, cilengitide (0.0005µM) substantially decreased S. 359 
aureus attachment to the vessel wall endothelium of the mice (Figure 5C&E).  360 
  361 
Staphylococcus aureus ClfA binding to αVβ3 inhibits proliferation and induces 362 
apoptosis in endothelial cells 363 
Uninfected sheared endothelial cells proliferated as expected over 24hrs however 364 
addition of S. aureus to endothelial cells significantly reduced the rate of proliferation 365 
(Figure 6A). Notably, addition of a S. aureus ΔClfA (Figure 6A) or addition of 366 
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cilengitide (Figure 6B) exhibited a significantly attenuated effect on endothelial cells 367 
proliferation compared to S. aureus.  368 
 369 
Given our finding that the endothelial cell number decreased following 24hrs in the 370 
presence of S. aureus, we examined whether this was due to apoptosis. To 371 
determine this, Annexin V exposure on the cell surface, a hall mark of apoptotic 372 
cells, was assessed by flow cytometry. Uninfected endothelial cells have a low level 373 
of apoptosis, however upon addition of S. aureus to the endothelial cells, apoptosis 374 
was significantly increased. Addition of S. aureus ΔClfA caused a significantly lower 375 
extent of apoptosis in the endothelial cells (Figure 6C). Similarly preincubation of 376 
endothelial cells with cilengitide led to a significant reduction in S. aureus induced 377 
apoptosis (Figure 6D).  378 
 379 
Staphylococcus aureus ClfA binding to αVβ3 induces increased vascular 380 
permeability 381 
We hypothesize that S. aureus ClfA binding to αVβ3 generates a signal resulting in 382 
an increase in permeability a common feature in patients with sepsis. To test this we 383 
measured the paracellular permeation passage of FITC-dextran 40kDa across a 384 
confluent monolayer of endothelial cells in the presence and absence of S. aureus. 385 
Addition of S. aureus to the sheared endothelial cells led to a significant increase in 386 
barrier permeability (Figure 7A). Addition of S. aureus ΔClfA failed to increase 387 
permeability compared to wildtype S. aureus. Similarly, inhibition of αVβ3 with 388 
cilengitide attenuated the increase in permeability induced by wildtype S. aureus. 389 
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(Figure 7A). Consistent with these results, immunofluorescent staining of VE-390 
cadherin on endothelial cells indicate tight barrier formation in uninfected samples 391 
(Figure 7B). However, upon infection with S. aureus, VE-cadherin expression in the 392 
cell membranes is reduced, suggesting cell-cell detachment (Figure 7C). Consistent 393 
with our previous data using the ΔClfA strain or treating the endothelial cells with 394 
cilengitide restores VE-cadherin expression and thus barrier integrity (Figure 7D and 395 
E, respectively). 396 
 397 
DISCUSSION 398 
In the present study, we used a dynamic model of endothelial infection that 399 
replicates endothelial conditions experienced during sepsis. Using sheared human 400 
endothelial cells we showed significant S. aureus binding in the presence of human 401 
plasma and low level of TNFα. Attachment was mediated by the S. aureus major cell 402 
wall protein, ClfA which in the presence of plasma fibrinogen bound to αVβ3 403 
expressed on human endothelial cells. Binding resulted in calcium mobilization, 404 
granule exocytosis and vWf deposition on the surface of the endothelial cells. Within 405 
24hrs of S. aureus attachment there was a significant loss of barrier integrity 406 
resulting in increased endothelial permeability. In parallel with elevated permeability 407 
following S. aureus infection of endothelial cells, we also observed impaired 408 
proliferation in conjunction with elevated apoptosis. Strikingly, the αVβ3 antagonist 409 
cilengitide, significantly reduced all these effects.  410 
 411 
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S. aureus ClfA is a major MSCRAMM expressed on the surface of all naturally 412 
occurring S. aureus strains and most critically uses fibrinogen to bridge to endothelial 413 
cells. While S. aureus expresses other fibrinogen binding proteins such as Clumping 414 
factor B (ClfB) and fibronectin binding protein A and B (FnbpA and FnbpB) we could 415 
not detect any involvement in their ability to bind to endothelial cells (data not 416 
shown). Although our experimental design allowed us to isolate the S. aureus-417 
Endothelial cell interaction mechanism triggered by ClfA, the participation of other 418 
MSCRAMMs in clinical isolates of S. aureus cannot be ruled out. Indeed S. aureus 419 
ΔClfA exhibited a residual capacity of binding endothelial cells in vitro and in vivo, as 420 
well as in proliferation and apoptosis.  421 
 422 
Previously, vWf has been shown to mediate S. aureus attachment to activated 423 
endothelium under flow conditions via vwbp[4]. In the current study we demonstrate 424 
that S. aureus ClfA binding to αvβ3 induces calcium mobilization and exocytosis of 425 
Weibel-Palade bodies leading to deposition of vWf on the surface of endothelial 426 
cells. These results suggest that ClfA binding to αVβ3 provides the signal that leads 427 
to vWf deposition on the surface of the endothelial cell and therefore provide a 428 
platform for the S. aureus vwbp to attach and anchor the bacteria to the vessel wall. 429 
Typically ultra large vWf multimers deposited on the surface of endothelial cells are 430 
cleaved by a disintegrin and metalloproteinase with a thrombospondin type I motif, 431 
member 13 (ADAMTS13) [31]. However patients with sepsis have an acquired 432 
deficiency of ADAMTS13 that leads to an inability to break down these ultra large 433 
vWf multimers[32] thus resulting in more S. aureus attachment and rapid progression 434 
of sepsis. Although the vWf has been reported to bind αVβ3 under shear the 435 
contribution of this interaction in sepsis is still unclear[33].  436 
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 437 
During sepsis the vascular endothelial barrier breaks down which facilitates the 438 
passage of large molecules (such as albumin and plasma proteins) and leukocytes 439 
from the blood into the subendothelial compartment. This leads to life threatening 440 
oedema in the lungs, kidneys and brains of septic patients[34]. Using a dynamic ex 441 
vivo model that represents the physiological state of human blood vessels by forming 442 
tight junctions between the cells, we support this finding in vitro where S. aureus 443 
infection leads to a significant increase in endothelial permeability. Vascular 444 
endothelial (VE)-cadherin is a type I transmembrane protein and is an important 445 
adherens junction protein that plays a critical role in the maintenance and control of 446 
cell contacts that form the endothelial barrier. Significantly we demonstrate that 447 
addition of S. aureus to the sheared endothelial cells destabilizes the VE-cadherin 448 
interactions leading to an increase in permeability. Using a strain deficient in 449 
expression of ClfA or blocking αVβ3 with cilengitide resulted in a significant reduction 450 
in endothelial cell permeability induced by S. aureus and a stabilization of the VE-451 
cadherin contacts. We therefore suggest that preventing the ClfA αVβ3 interaction 452 
with cilengitide arrests the signal that leads to apoptosis and subsequent reduction in 453 
VE-cadherin expression, thus reducing the possibility of an increase in vascular 454 
permeability. Interestingly, Alghisi et al., previously demonstrated that cilengitide 455 
binding to αVβ3 on HUVEC resulted in down-regulation of VE-cadherin, thus 456 
contributing to increased vascular permeability[35]. We did not find this in our 457 
studies, however the concentration of cilengitide used in the Alghisi study was 200 458 
times higher than what we used in our study (10µM versus 0.05µM, respectively).  459 
 460 
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Three integrins containing the αV subunit are expressed in endothelial cells: αVβ1, 461 
αVβ3 and αVβ5[36-38], of which only integrin αVβ3 has been described to bind 462 
fibrinogen with high affinity[39], and is thus the relevant integrin in fibrinogen-ClfA 463 
mediated S. aureus binding to endothelial cells. Cilengitide was originally developed 464 
for the treatment of glioblastomas and reached phase III clinical trials however 465 
treatment did not improve the overall survival of patients and the trials were 466 
suspended[40, 41]. The current study provides consistent evidence that cilengitide 467 
prevents ClfA from binding αVβ3 on the endothelium, impeding the activation of 468 
injurious pathways resulting in apoptosis and increased vascular permeability. We 469 
propose that Cilengitide could slow infection from progressing to multi-organ failure 470 
without compromising normal endothelial cell function. We therefore suggest that 471 
cilengitide represents a candidate drug for investigation of its potential therapeutic 472 
value, used in conjunction with antibiotics, to treat sepsis early in the infective 473 
process.  474 
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 631 
FIGURE LEGENDS 632 
 633 
Figure 1. Sheared endothelial cells constitute a dynamic ex vivo model for the 634 
study of S. aureus binding. S. aureus adhesion to sheared endothelial cells, tested 635 
in the presence and absence of plasma and 10 ng/ml of TNFα. Equal amounts of 636 
endothelial cells were plated in microtitre plates. After blocking with 1%BSA, cells 637 
were infected with known amounts of SYBR Green I labelled S. aureus Newman 638 
(107) were added and incubated for 1 hr. Total fluorescence was measured on a 639 
plate reader at 485/535 nm. Unbound bacteria were removed by gently washing with 640 
PBS, and attached bacteria fluorescence was acquired. Results are expressed as 641 
number of bacteria attached per well. * P<0.05 vs. all other groups.  642 
 643 
Figure 2. Clumping factor A binds fibrinogen to bridge S. aureus to endothelial 644 
cells. Binding of bacteria to sheared Endothelial cells (10 dyn/cm2-24 hours) was 645 
measured at a MOI of 400 in the presence of plasma and 10ng/ml TNFα, as 646 
previously described. (A) Binding of S. aureus wild type (Newman), deficient in 647 
protein A (ΔSpA) or deficient in clumpling factor A (ΔClfA) to sheared Endothelial 648 
cells. (B) Binding of the surrogate host Lactococcus lactis, either mock transfected or 649 
expressing SpA or ClfA to sheared Endothelial cells..(C) The absence of the SpA 650 
and ClfA cell wall proteins was confirmed by dot blot. Blots are representative of 651 
three independent experiments. (D) Expression of ClfA and SpA on L. lactis was 652 
confirmed by dot immunoblots of whole bacteria cell lysates. Images are 653 
representative of three independent experiments. (E) Effect of the presence of 654 
plasma, IgG (1 mg/ml) or fibrinogen (4 mg/ml) on L. lactis ClfA binding to sheared 655 
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Endothelial cells. (F) Binding to sheared Endothelial cells of L. lactis expressing ClfA 656 
or ClfA PY in the presence of 4 mg/mL fibrinogen. N=3, *P<0.05 vs. wildtype, 657 
**P<0.05 vs. all other groups, ANOVA. 658 
 659 
Figure 3. ClfA induces intracellular Ca2+ increase and von Willebrand factor 660 
deposition the surface of endothelial cells. Endothelial cells were sheared for 24 661 
hours, trypsinized and lawned in Ibidi microperfusion chambers. Cells were 662 
preloaded with Fluo-4 AM for intracellular Ca2+ detection by epifluorescence 663 
microscopy under flow (10 dyn/cm2) at 37⁰C with 40X oil immersion lens objective on 664 
a Zeiss AxioObserverZ1 epi-fluorescence microscope coupled to a CCD camera and 665 
equipped with mercury lamp and appropriate filters. Light intensity was adjusted to 666 
prevent signal saturation. After initial 2 minutes perfusion with HEPES solution 667 
containing 10ng/ml TNFα and 4 mg/ml fibrinogen, the perfusate was switched, in 668 
order to induce infection, to the same solution containing OD600 0.6-0.7 L. lactis WT 669 
(n=8), L. lactis ClfA (n=6) or no bacteria (uninfected control, n=8). Samples were 670 
excited at 488 and >500nm emission was measured at regular time intervals. 671 
Representative “fire” pseudocolor images corresponding to (A) uninfected, (B) L. 672 
lactis WT infected and (C) L. lactis ClfA infected Endothelial cells, acquired 2 673 
minutes after the infection. Scale bar represents 50µm. (D) Fluo-4 semiquantitative 674 
timecourse expressed as F/F0 (F0=at the time of infection), for uninfected 675 
(continuous line), L. lactis WT (dashed line) and L. lactis ClfA (dotted line) infected 676 
Endothelial cells. Arrow indicates the start of infection. For vWf measurements, 677 
sheared Endothelial cells (24 hours) were exposed to L. lactis WT or L. lactis ClfA in 678 
the presence of fibrinogen (4 mg/mL) and TNFα (10 ng/mL) for 60 minutes under 10 679 
dyn/cm2 shear. Uninfected cells were used as control. Same ImageJ brightness and 680 
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contrast settings were applied to all displayed images. Scale bar represents 50 µm. 681 
Representative images of surface vWf (yellow) detected by immunofluorescence of 682 
non-permeabilised cells (plan-apochromat 63x/1.40 oil immersion objective (Ex/Em 683 
488nm/>505nm for vWf and 350/> 400nm for DAPI). corresponding to uninfected 684 
(E), infected with L. lactis WT (F) and infected with L. lactis ClfA groups (G). Nuclei 685 
were stained with DAPI (blue).  686 
(H) Semiquantitative analysis of vWf levels in the surface of Endothelial cells, 687 
computed as fluorescence/cell (see methods) (n=3). *P<0.05 vs. all other groups, 688 
ANOVA. 689 
 690 
Figure 4.  Fibrinogen bridges ClfA to endothelial cell αVβ3 integrin. (A) Sheared 691 
endothelial cells (10 dyn/cm2-24 hours) in the presence of fibrinogen (4 mg/mL) and 692 
TNFα (10 ng/mL) were preincubated with either isotype/vehicle control, anti-ICAM1 693 
(20 µg/ml), Anti-α5β1 (20 µg/ml) or cilengitide (0.05 µM) for 30 minutes prior to 694 
addition of L. lactis ClfA (n=3, *P<0.05 vs all other groups, ANOVA0). (B) Effect of 695 
0.05 µM cilengitide on S. aureus binding to sheared endothelial cells (n=3, *P<0.05, 696 
t-test). (C) Effect of cilengitide (0.05 µM) on L. lactis ClfA adhesion to immobilized 697 
purified  αVβ3 integrin cilengitide (n=3, **P<0.001). 698 
 699 
Figure 5. S. aureus in vivo adhesion to the endothelium is mediated by ClfA. S. 700 
aureus were injected into the right jugular vein of anesthetized mice, and their 701 
adhesion to the activated endothelium was measured by timelapse fluorescence 702 
recording in the mesenteric veins (one image per second). Representative images 703 
showing adhesion of fluorescent S. aureus WT to mesenteric veins (A). Adhesion is 704 
diminished when ClfA is knocked out (S. aureus ΔClfA) (B) and is virtually abolished 705 
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by pre-administration of intravenous cilengitide (0.005µM) (C). Quantitative bacteria 706 
adhesion computed as bacteria fluorescence average over 40 seconds (see 707 
methods). (D) Knocking out ClfA in S. aureus reduces attachment to endothelium, 708 
(n=10-17, *P<0.05, t-test), (E) S. aureus-endothelium binding is significantly reduced 709 
by 0.005µM cilengitide and ΔClfA (n=11-17, **P<0.005, t-test). 710 
 711 
Figure 6. Loss of Endothelial cells proliferation and induction of apoptosis 712 
induced by S. aureus is attenuated by deleting ClfA or blocking αVβ3 integrin 713 
with cilengitide. 1.5x105 cells were seeded per well (time=0), and Endothelial cells 714 
proliferation was evaluated as the cell count after 24 hours (time=24). (A) Endothelial 715 
cells proliferation evaluated for uninfected cells (continuous line), infected with S. 716 
aureus Newman (dotted line) and S. aureus ΔClfA (dashed line) (n=3, * and 717 
**P<0.05 vs. all other groups, ANOVA). (B) Endothelial cells proliferation evaluated 718 
for uninfected cells (continuous line), infected with S. aureus Newman (dotted line) 719 
and with S. aureus Newman in the presence of  αVβ3 integrin blocker cilengitide 720 
0.05 µM (dashed line) (n=3, * and **P<0.05 vs. all other groups, ANOVA). For 721 
apoptosis assays endothelial cells were detached from plates by trypsinization and 722 
stained with Annexin-V antibody. Apoptosis levels were assessed by flow cytometry.  723 
(C) S. aureus Newman induced a significant increase in apoptosis, that was not 724 
observed with S. aureus ΔClfA (n=3, *P<0.05 vs. all other groups). (D) αVβ3 integrin 725 
blocker cilengitide 0.05µM reduced apoptosis induced by S. aureus infection (n=3, * 726 
and **P<0.05 vs. all other groups, ANOVA). 727 
 728 
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Figure 7. Increase of endothelial permeability induced by S. aureus binding 729 
through ClfA is reduced by blocking αVβ3 integrin with a low concentration of 730 
cilengitide. (A) The barrier function of Endothelial cells monolayers was assessed 731 
by measuring the passage of FITC-dextran 40KDa added in the top compartment to 732 
the bottom compartment using transwell inserts. Endothelial cells were infected with 733 
S. aureus Newman or ΔClfA for 24 hours (MOI 400). After 24 hours, concentration of 734 
FITC-dextran on the bottom compartment was measured on a fluorescence plate 735 
reader. Values were calibrated between 100% permeability (absence of endothelial 736 
cells and bacteria) and 0% permeability (uninfected monolayer of sheared 737 
endothelial cells) (n=3, * and **P<0.05, ANOVA). In order to visualise the expression 738 
of VE-cadherin following infection endothelial cells were fixed, permeabilised and 739 
incubated with antibody against VE-cadherin (primary) and Alexa Fluor® 488-740 
conjugated (secondary).  Nuclei were stained with DAPI. Images were acquired with 741 
a fluorescence microscopy. Representative immunofluorescence images of three 742 
independent experiments showing (B) Uninfected endothelial cells, (C) S. aureus 743 
infected endothelial cells, (D) ΔClfA infected endothelial cells and (E) S. aureus 744 
infected endothelial cells in the presence of cilengitide.  745 
TABLE 1. Integrin aVb3 is significantly increased on human aortic endothelial 746 
cells following infection with Staphylococcus aureus. Expression of αVβ3 was 747 
measured by flow cytometry in the presence and absence of TNFα (10ng/ml). 748 
Sheared endothelial cells were incubated with rabbit polyclonal anti-αVβ3 or isotype 749 
control. Primary antibodies were incubated with the endothelial cells for 1hr at 37ºC 750 
followed by a FITC labelled secondary antibody in the dark. αVβ3 expression was 751 
analysed on a FACS Calibur flow cytometer (Becton Dickinson, Oxford, UK) on the 752 
Fl-1 channel. P<0.05. 753 
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 754 
FIGURE LEGENDS (Supplementary) 755 
Supplementary Figure 1.Development of a dynamic ex vivo model that 756 
represents the physiological state of human blood vessels. Confluent 757 
monolayers of HAoECs were fixed, permeabilized and incubated with antibody 758 
against VE-cadherin (primary) and Alexa Fluor® 488-conjugated (secondary). Nuclei 759 
were stained with DAPI. Images were acquired with a fluorescence microscopy. 760 
Immunofluorescence images are representative of three independent experiments. 761 
Statically grown cells display random orientation and patches with lack of VE-762 
cadherin staining despite the presence of nuclei (A); whereas for sheared cells, VE-763 
cadherin and DAPI staining show alignment of cells and nuclei parallel to the 764 
direction of the flow (B). VE-cadherin expression determined by western blot of 765 
protein homogenates from static and sheared HAoECs (C). S. aureus adhesion to 766 
static and sheared endothelial cells, tested in the presence of plasma and 10 ng/ml 767 
of TNFα. After priming with plasma and/or TNFα, equal amounts of endothelial cells 768 
were blocked with 1%BSA and subsequently infected with fluorescently SYBR Green 769 
I stained S. aureus Newman at a MOI of 400 for 1 hr. Total fluorescence was 770 
measured on a plate reader at 485/535 nm. Unbound bacteria were removed by 771 
gently washing with PBS, and attached bacteria fluorescence was acquired (D) (n=3, 772 
*P<0.01). 773 
 774 
Supplementary Figure 2.Fibrinogen plays a critical role in the attachment of S. 775 
aureus to human aortic endothelial cells. The ability of Staphylococcus aureus to 776 
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bind to endothelial cells in the presence and absence of fibrinogen was tested. Equal 777 
amounts of endothelial cells were plated in 96 well microtitre plates in the presence 778 
of TNFα (10ng/ml). Fibrinogen (1mg/ml) or vehicle control (PBS) was added for 1 hr 779 
at 37ºC. After blocking with 1% BSA, endothelial cells were infected with SYBR 780 
Green I labelled S. aureus Newman (1x107) for 1 hr. Total fluorescence was 781 
measured on an plate reader at 485/535 nm. Unbound bacteria were removed by 782 
gently washing with PBS, and attached bacteria fluorescence was acquired. Results 783 
are expressed as number of bacteria attached per well. Black bars = Staphylococcus 784 
aureus, White bars = Staphylococcus aureus deficient in expression of ClfA. *P<0.05 785 
vs. all other groups using ANOVA. 786 
 787 
Supplementary figure 3 Cilengitide alone does not induce any toxic effects on 788 
human aortic endothelial cells. Confluent monolayers of endothelial cells treated 789 
with 10 ng/ml TNFα for 4 hrs were exposed to a vehicle control (A) or 0.05µM 790 
cilengitide (B) for 24 hours to assess viability of cells.  Cell metabolic activity was 791 
measured using a MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 792 
bromide) assay (C). Apoptosis was measured using flow cytometric analysis of 793 
Annexin V staining (D). Barrier integrity was measured by visualising fluorescently 794 
labelled tight junction protein, VE-cadherin in the presence and absence of 795 
cilengitide.  Representative images of VE-cadherin (green) of control (E) and 24 hour 796 
0.05 µM cilengitide treated (F) sheared endothelial cell monolayers.  797 
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